Shaukat Mohammed Khalid, S., Abbas, M. (2021). Outcome of Frontline Therapy of Hodgkin’s Lymphoma Patients in Baghdad Hematology Centering the Medical City. Alustath, 21(3), 280-287. doi: 10.52573/ipmj.2021.175761
Safa Mohammed Shaukat Mohammed Khalid; Mohammed Saleem Abbas. "Outcome of Frontline Therapy of Hodgkin’s Lymphoma Patients in Baghdad Hematology Centering the Medical City". Alustath, 21, 3, 2021, 280-287. doi: 10.52573/ipmj.2021.175761
Shaukat Mohammed Khalid, S., Abbas, M. (2021). 'Outcome of Frontline Therapy of Hodgkin’s Lymphoma Patients in Baghdad Hematology Centering the Medical City', Alustath, 21(3), pp. 280-287. doi: 10.52573/ipmj.2021.175761
Shaukat Mohammed Khalid, S., Abbas, M. Outcome of Frontline Therapy of Hodgkin’s Lymphoma Patients in Baghdad Hematology Centering the Medical City. Alustath, 2021; 21(3): 280-287. doi: 10.52573/ipmj.2021.175761

Outcome of Frontline Therapy of Hodgkin’s Lymphoma Patients in Baghdad Hematology Centering the Medical City

Iraqi Postgraduate Medical Journal
Article 5, Volume 21, Issue 3, July 2022, Pages 280-287    PDF (457.59 K)
DOI: 10.52573/ipmj.2021.175761
Authors
Safa Mohammed Shaukat Mohammed Khalid1; Mohammed Saleem Abbas2
1Hematologist in Hereditary Bleeding Disorders Center in Pediatric Teaching Hospital the Medical City, Baghdad, Iraq
2Consultant Hematologist in Baghdad Hematology Center in the Medical City, Baghdad, Iraq
Abstract
BACKGROUND:
Hodgkin’s lymphoma is one of most curable lymphoid malignancy. Here we conducted in this study the outcome of frontline therapy in adult Hodgkin’s lymphoma patients.
AIM OF STUDY:  
1. To evaluate   the results of first line treatment with ABVD chemotherapy protocol in patients with Hodgkin’s lymphoma in this study.
2. To find predictors associated with poor outcome of   first line treatment with ABVD chemotherapy protocol in patients with Hodgkin’s lymphoma in this study.
METHODS:  
This  is  a    retrospective and prospective study  in which  information  was gathered from Baghdad  hematology  center involving 50  patients  who  were  diagnosed  with Hodgkin’s lymphoma   from 1/1/ 2017  until  mid of  2019 and treated with frontline therapy, ABVD chemotherapy protocol.
RESULTS:  
The mean age of diagnosis was 29.6 ±12.12 year.  Nodular sclerosis   was the predominant subtypes constituted   (62%) of patients.  Advanced stage disease involved 86% of patients.  At  interim  evaluation by imaging studying including either ultrasound and CT scan or Pet scan according to availability ,  complete  remission, partial  remission and   progressive  disease involving    58% , 26%  and  16% of patients respectively. Two years progression free survival was 68.95%. There was a strong correlation between lymphocytopenia and progression free survival.  In  this  study,  univariate  analysis  showed  that  initial    lymphocytopenia was poorly associated with chance of achieving complete  remission    at  end  of treatment.
CONCLUSION:
The  outcome  of  ABVD  in  this  study  shows    lymphocytopenia was poorly associated with complete  remission    at  end  of treatment of patients.
 
 
Keywords
Hodgkin’s lymphoma; frontline therapy; Outcome; progression free survival
References
  1. Shanbhag  S,  Ambinder  RF.  Hodgkin  lymphoma:  a  review  and  update  on recent  progress.  CA:  a  cancer  journal  for  clinicians.  2018;68:11632.
  2. Townsend  W,  Linch  D.  Hodgkin's  lymphoma  in  adults.  The  Lancet.  2012;380:836-47.
  3. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk‐stratification, and management. American journal of hematology. 2016;91:434-42.
  4. Follows  GA,  Ardeshna  KM,  Barrington  SF,  Culligan  DJ,  Hoskin  PJ,  Linch D,  Sadullah  S,  Williams  MV,  Wimperis  JZ,  British  Committee  for Standards  in  Haematology.  Guidelines  for  the  first  line  management  of classical  Hodgkin  lymphoma.  British  journal  of  haematology.  2014;166:34-49.
  5. Shafi  RG,  Al-Mansour  MM,  Kanfar  SS,  Al  Hashmi  H,  Alsaeed  A,  AlFoheidi  M,  Ibrahim  EM.  Hodgkin  lymphoma  outcome:  a  retrospective study  from  3  tertiary  centers  in  Saudi  Arabia.  Oncology  research  and treatment.  2017;40:288-92.
  6. Mohammed  zaki  LB,  Hasan  KM,  Polus  RK,  Yassin  AK. Clinicopathological,  immunohistochemical  charachtaristic  and  the  outcome of  Hodghkin  lymphoma  patients  in  Erbil  city,  Iraq.  Iraqi  Journal  of Hematology.  2019;8:14.
  7. Rigacci  L,  Puccini  B,  Zinzani  PL,  Biggi  A,  Castagnoli  A,  Merli  F, Balzarotti  M,  Stelitano  C,  Spina  M,  Vitolo  U,  Stefoni  V.  The  prognostic value  of  positron  emission  tomography  performed  after  two  courses (INTERIM‐PET)  of  standard  therapy  on  treatment  outcome  in  early  stage Hodgkin  lymphoma:  A  multicentric  study  by  the  fondazione  italiana linfomi  (FIL).  American  journal  of  hematology.  2015;90:499-503.
  8. Iannitto  E,  Minardi  V,  Gobbi  PG,  Calvaruso  G,  Tripodo  C,  Marcheselli  L, Luminari  S,  Merli  F,  Baldini  L,  Stelitano  C,  Callea  V.  Response-Guided ABVD  Chemotherapy  plus  Involved-Field  Radiation  Therapy  for Intermediate-Stage  Hodgkin  Lymphoma  in  the  Pre–Positron  Emission Tomography  Era:  A  Gruppo  Italiano  Studio  Linfomi  (GISL)  Prospective Trial.  Clinical  Lymphoma  and  Myeloma.  2009;9:138-44.
  9. Boo  YL,  Ting  Y,  Siew  H,  Yap  DF,  Toh  SG,  Lim  SM.  Clinical  features  and treatment  outcomes  of  Hodgkin  lymphoma:  A  retrospective  review  in  a Malaysian  tertiary  hospital.  Blood  research.  2019;54:210-17.
10. Montalbán  C,  García  JF,  Abraira  V,  González-Camacho  L,  Morente  MM, Bello  JL,  Conde  E,  Cruz  MA,  García-Sanz  R,  García-Laraña  J,  Grande  C. Influence  of  biologic  markers  on  the  outcome  of  Hodgkin's  lymphoma:  a study  by  the  Spanish  Hodgkin's  Lymphoma  Study  Group.  Journal  of Clinical  Oncology.  2004;22:1664-73.

11. Barnes  JA,  LaCasce  AS,  Zukotynski  K,  Israel  D,  Feng  Y,  Neuberg  D, Toomey  CE,  Hochberg  EP,  Canellos  GP,  Abramson  JS.  End-of-treatment but  not  interim  PET  scan  predicts  outcome  in  nonbulky  limited-stage Hodgkin’s  lymphoma.  Annals  of  oncology.  2010  ;22:910-15.

12. Stamatoullas  A,  Brice  P,  Bouabdallah  R,  Mareschal  S,  Camus  V,  Rahal  I, Franchi  P,  Lanic  H,  Tilly  H.  Outcome  of  patients  older  than  60  years  with classical  Hodgkin  lymphoma  treated  with  front  line  ABVD  chemotherapy: frequent  pulmonary  events  suggest  limiting  the  use  of  bleomycin  in  the elderly.  British  journal  of  haematology.  2015;170:179-84.

13. Makita  S,  Maruyama  D,  Maeshima  AM,  Taniguchi  H,  Miyamoto  KI, Kitahara  H,  Fukuhara  S,  Munakata  W,  Kobayashi  Y,  Itami  J,  Tobinai  K. Clinical  features  and  outcomes  of  139  Japanese  patients  with  Hodgkin lymphoma.  International  journal  of  hematology.  2016  ;104:236-44.

14. Smolewski  P,  Robak  T,  Krykowski  E,  Blasiñska-Morawiec  M, Niewiadomska  H,  Pluzanska  A,  Chmielowska  E,  Zambrano  O.  Prognostic factors  in  Hodgkin’s  disease:  multivariate  analysis  of  327  patients  from  a single  institution.  Clinical  Cancer  Research.  2000;6:1150-60.

15. Law  MF,  Ng  TY,  Chan  HN,  Lai  HK,  Ha  CY,  Leung  C,  Ng  C,  Yeung  YM, Yip  SF.  Clinical  features  and  treatment  outcomes  of  Hodgkin's  lymphoma in  Hong  Kong  Chinese.  Archives  of  medical  science:  AMS.  2014;10:498.

16. Hutchings  M,  Loft  A,  Hansen  Metal.  FDG-PET  after  two  cycles  of  chemo therapy  predicts  treatment  failure  and  progression-free  survival  in  Hodgkin lymphoma.  Blood 2006;107:52–59.

17. Lapuz  C,  Enjeti  AK,  O'Brien  PC,  Capp  AL,  Holliday  EG,  Gupta  S. Outcomes  and  relapse  patterns  following  chemotherapy  in  advanced Hodgkin  lymphoma  in  the  positron  emission  tomography  era.  Blood  and Lymphatic  Cancer.  2018;8:13.

18. Kumar  A,  Burger  IA,  Zhang  Z,  Drill  EN,  Migliacci  JC,  Ng  A,  La  Casce  A, Wall  D,  Witzig  TE,  Ristow  K,  Yahalom  J.  Definition  of  bulky  disease  in early  stage  Hodgkin  lymphoma  in  computed  tomography  era:  prognostic significance  of  measurements  in  the  coronal  and  transverse  planes. haematologica.  2016;101:1237-43.

19. Porrata  LF,  Ristow  K,  Colgan  JP,  Habermann  TM,  Witzig  TE,  Inwards  DJ, Ansell  SM,  Micallef  IN,  Johnston  PB,  Nowakowski  GS,  Thompson  C. Peripheral  blood  lymphocyte/monocyte  ratio  at  diagnosis  and  survival  in classical  Hodgkin’s  lymphoma.  Haematologica.  2012;97:262-69.

20. Maddi  RN,  Linga  VG,  Iyer  KK,  Chowdary  JS,  Gundeti  S,  Digumarti  R, Paul  TR.  Clinical  profile  and  outcome  of  adult  Hodgkin  lymphoma: experience  from  a  tertiary  care  institution.  Indian  journal  of  medical  and paediatric  oncology:  official  journal  of  Indian  Society  of  Medical  & Paediatric  Oncology.  2015;36:255.

 

Statistics
Article View: 81
PDF Download: 42


Journal Management System. Powered by ejournalplus.com